Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: A double-blind randomized trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 70, Issue 3, 2015, Pages 242-249

  Chen, Beatrice A ^a,b   Panther, Lori ^c   Marzinke, Mark A ^d   Hendrix, Craig W ^d   Hoesley, Craig J ^e   Van Der Straten, Ariane ^f,g   Husnik, Marla J ^h   Soto Torres, Lydia ⁱ   Nel, Annalene ^j   Johnson, Sherri ^k   Richardson Harman, Nicola ^l   Rabe, Lorna K ^b   Dezzutti, Charlene S ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c FENWAY INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

^f RTI INTERNATIONAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

^k FAMILY HEALTH INTERNATIONAL   (United States)

^l ALPHA STATCONSULT LLC   (United States)

more..

Author keywords

Dapivirine; Ex vivo challenge assay; Maraviroc; Microbicide; Pre exposure prophylaxis; Vaginal rings

Indexed keywords

DAPIVIRINE; MARAVIROC; PLACEBO; ANTIINFECTIVE AGENT; CYCLOHEXANE DERIVATIVE; DRUG COMBINATION; PYRIMIDINE DERIVATIVE; TMC120-R147681; TRIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DEVICE SAFETY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; EX VIVO STUDY; EXPLANT; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERTENSION; METRORRHAGIA; MIGRAINE; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PATIENT COMPLIANCE; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; UTERINE CERVIX BIOPSY; UTERINE CERVIX MUCUS; VAGINA RING; ADOLESCENT; BLOOD; DRUG COMBINATION; HALF LIFE TIME; INTRAVAGINAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CYCLOHEXANES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HUMANS; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 84944448396     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000702     Document Type: Conference Paper

References (35)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
2. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
3. van der Straten A, Van Damme L, Haberer JE, et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26:F13-F19.
4. Nel A, Kamupira M, Woodsong C, et al. Safety, acceptability, and pharmacokinetic assessment (adherence) of monthly dapivirine vaginal microbicide rings (Ring-004) for HIV prevention. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA.
5. Nel AM, Coplan P, Smythe SC, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses. 2010;26:1181-1190.
6. Nel AM, Coplan P, van de Wijgert JH, et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS. 2009;23:1531-1538.
7. Nel AM, Smythe SC, Habibi S, et al. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr. 2010;55: 161-169.
8. Nel A, Haazen W, Nuttall J, et al. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28:1479-1487.
9. Akil A, Agashe H, Dezzutti CS, et al. Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention. Pharm Res. 2015;32:458-468.
10. Akil A, Parniak MA, Dezzutti CS, et al. Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv Transl Res. 2011;1:209-222.
11. Microbicide Trials Network. Phase III trial of dapivirine ring begins in Africa: ASPIRE testing new HIV prevention approach for women. 2012. Available at: http://www.mtnstopshiv.org/node/4546. Accessed May 6, 2014.
12. International Partnership for Microbicides. First efficacy trial of a micro-bicide ring to prevent HIV is underway. 2012. Available at: http://www. ipmglobal.org/publications/first-efficacy-trial-microbicide-ring-prevent-hiv-underway. Accessed May 6, 2014.
13. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis. 2011;52:780-787.
14. Else LJ, Taylor S, Back DJ, et al. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16:1149-1167.
15. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
16. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-147.
17. Stringer JS, McConnell MS, Kiarie J, et al. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med. 2010;7:e1000233.
18. Zu Knyphausen F, Scheufele R, Kucherer C, et al. First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study. PLoS One. 2014;9:e95956.
19. Borrego P, Taveira N. HIV-2 susceptibility to entry inhibitors. AIDS Rev. 2013;15:49-61.
20. Baalwa J, Wang S, Parrish NF, et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2013;436:33-48.
21. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206:1273-1289.
22. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105: 7552-7557.
23. Division of AIDS Table for Grading the Severity of Adult and Pediatric Events Version 1.0, December, 2004; Clarification August 2009. Available at: http://rsc.tech-res.com/document/safetyandpharmacovigilance/table- for-grading-severity-of-adult-pediatric-adverse-events.pdf. Accessed May 20, 2014.
24. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Addendum 1 Female Genital Grading Table for Use in Microbicide Studies. Available at: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Addendum-1-Female-Genital-Grading- Table-v1-Nov-2007.pdf. Accessed May 20, 2014.
25. WHO/CONRAD. Manual for the Standardization of Colposcopy for the Evaluation of Vaginal Products, Update 2004. Geneva, Switzerland; CONRAD/WHO, 2004. Available at: http://www.who.int/reproductivehealth/publications/rtis/RHR-04.2/en/index.html. Accessed January 22, 2014.
26. Emory JF, Seserko LA, Marzinke MA. Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma. Clinica Chim Acta. 2014;431:198-205.
27. Parsons TL, Emory JF, Seserko LA, et al. Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis. J Pharm Biomed Anal. 2014; 98:407-416.
28. Seserko LA, Emory JF, Hendrix CW, et al. The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. Bioanalysis. 2013;5: 2771-2783.
29. Dezzutti CS, Uranker K, Bunge KE, et al. HIV-1 infection of female genital tract tissue for use in prevention studies. J Acquir Immune Defic Syndr. 2013;63:548-554.
30. Fletcher P, Harman S, Azijn H, et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2009;53:487-495.
31. Malcolm RK, Woolfson AD, Toner CF, et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother. 2005;56:954-956.
32. Woolfson AD, Malcolm RK, Morrow RJ, et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm. 2006;325:82-89.
33. Fetherston SM, Boyd P, McCoy CF, et al. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Eur J Pharm Sci. 2012;48:406-415.
34. Abel S, Back DJ, Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther. 2009;14:607-618.
35. Zhou T, Hu M, Cost M, et al. Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research. AIDS Res Hum Retroviruses. 2013;29:1496-1503.